Project Grant R21NS135321
- This $654,593 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, aims to develop structure-guiding tools to study the role of choline in the development of congenital hydrocephalus. The key objectives are: 1) Determine the structures of the FLVCR1 and FLVCR2 choline transporters using cryo-electron microscopy to generate functional...
- This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will support research on the cerebrospinal fluid (CSF) system in children with autism spectrum disorder (ASD). The $165,000 award, with a performance period from August 1, 2025 to July 31, 2027, will leverage data from the Autism Brain Imaging Data Exchange II to assess perivascular space measures and choroid...
- The National Institute of Child Health and Human Development (NICHD) awarded a $441,375 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to Children's Hospital Medical Center in Cincinnati, Ohio. The project aims to develop "Microglia-Integrated Brain Organoids for Gaucher Disease Modeling and Therapeutic Discovery". The grant will support the creation of brain organoid models that incorporate microglia to study the mechanisms of...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders", provides $230,904 to Boston Children's Hospital from January 1, 2025 to December 31, 2029. The award will support research to identify novel genetic causes of infantile epilepsies and evaluate the impact of genetic diagnosis on patient outcomes and families. Key objectives include applying...
- This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
- The National Human Genome Research Institute (NHGRI) awarded a $470,250 Project Grant (CFDA 93.172 - Human Genome Research) to Children's Hospital Los Angeles (CHLA) to explore the perspectives of diverse parents on issues related to pediatric genome testing, research, and data management. The award will fund a qualitative pilot study utilizing focus groups, interviews, and a survey to: (1) examine attitudes towards genome sequencing for clinical testing and research with a focus on...
- This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $800,485 to Oregon Health & Science University (OHSU) to investigate the role of human-specific 3D genome conformation in brain development and disease. The key research objectives are to: 1) analyze Hi-C data from cortical neural progenitor cells and neurons derived from human, chimpanzee, orangutan, and rhesus macaque to identify human-specific...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of the ZIC2 transcription factor in regulating hedgehog signaling and chromatin dynamics during the development of the cerebral cortex. The $149,294 award, granted on July 4, 2025, will enable researchers at the University of Wisconsin - Madison...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $461,528 to the University of Connecticut Health Center (UCHC) to create the first human-based cellular model of Hao-Fountain syndrome. The goal is to understand the effect of disease-linked mutations on the enzymatic function of USP7 and on neuron differentiation and morphology....
- This Project Grant award of $5,949,022, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to identify novel therapeutic targets for treating cerebral amyloid angiopathy (CAA) and vascular contributions to cognitive impairment and dementia (VCID). The research, led by the Jackson Laboratory with sub-awards to Emory University, Rush...
UNDERSTANDING THE MECHANISMS OF CONGENITAL HYDROCEPHALUS USING GENOMIC SEQUENCING APPROACHES - CONGENITAL HYDROCEPHALUS (CH) IS A CONDITION THAT AFFECTS THE BRAIN AND RESULTS FROM AN ABNORMAL ACCUMULATION OF CEREBROSPINAL FLUID (CSF) WITHIN THE CEREBRAL VENTRICLES. THE CURRENT TREATMENTS FOR HYDROCEPHALUS ARE SURGICAL INTERVENTIONS, WHICH ACCOMPANIES A HIGH FAILURE RATE. ALTHOUGH EXTRINSIC FACTORS SUCH AS HEMORRHAGE OR INFECTIONS MAY CAUSE CH, RECENT STUDIES HAVE IDENTIFIED SOME CH-ASSOCIATED GENES OR MUTATIONS, EMPHASIZING THE ROLE OF GENETICS IN CH. HOWEVER, THESE GENETIC FACTORS ONLY ACCOUNT FOR APPROXIMATELY 22% OF SPORADIC CH CASES, AND MANY CASES REMAIN UNSOLVED. THEREFORE, THERE IS AN URGENT NEED TO ACCELERATE THE UNDERSTANDING OF CH THROUGH THE CUTTING-EDGE TECHNOLOGIES. WITHOUT LEVERAGING THESE NOVEL METHODS, THE DISCOVERY OF ADDITIONAL CAUSAL GENETIC FACTORS OF CH AND THE ADVANCEMENT OF ACCURATE DIAGNOSES AND TREATMENTS MAY BE HINDERED. THE LONG- TERM GOAL IS TO UNDERSTAND THE MOLECULAR MECHANISMS AND CONSEQUENCES UNDERLYING CH USING ORTHOGONAL PHENOMIC, GENETIC, AND MULTI-OMICS APPROACHES. THE OVERALL OBJECTIVE IS TO DEVELOP AND APPLY NEW GENOMICS TOOLS TO ADVANCE OUR UNDERSTANDING OF THE BIOLOGICAL MECHANISMS OF CH. THE CENTRAL HYPOTHESIS IS THAT THERE ARE ADDITIONAL GENETIC VARIATIONS IN GERMLINE OR SOMATIC AND/OR SPECIFIC MALFUNCTIONING CELL TYPES THAT CONTRIBUTE TO THE ETIOLOGY OF CH. TO TEST THIS HYPOTHESIS, THE PIS AND TEAM WILL PURSUE THE FOLLOWING AIMS. 1) COMPREHENSIVE CHARACTERIZATION OF ALL FORMS OF VARIATIONS IN BOTH GERMLINE AND SOMATIC TISSUE FROM CH PATIENTS WITH SHORT- AND LONG- READ WHOLE GENOME SEQUENCING. 2) IDENTIFICATION OF ABNORMAL CELL TYPES AND UNDERSTANDING THEIR FUNCTION AND CONTRIBUTION TO CH THROUGH SINGLE-CELL GENOMICS ANALYSIS. UPON COMPLETION, IT IS EXPECTED THAT NEW VARIATIONS EITHER IN THE GERMLINE OR SOMATIC MAY CONTRIBUTE TO CH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/8/25 | ||
| Not listed | $392.9k | 9/11/23 |